Could a lower dose of immunotherapy shrink colorectal tumors before surgery?
NCT ID NCT07523763
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether low doses of the immunotherapy drugs nivolumab or pembrolizumab can shrink tumors in people with a specific genetic type of colorectal cancer (MSI/dMMR) before they have surgery. The study involves 30 participants with stage II-III disease who will receive treatment for 6 months. The main goal is to see if the cancer disappears completely or shows a lasting response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab or pembrolizumab (low-dose immunotherapy)
What this could lead to
If successful, this could offer a less toxic, pre-surgery treatment option for certain colorectal cancers, potentially avoiding more aggressive therapies.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Low doses might be less effective, and side effects from immunotherapy are still possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
N.N. Blokhin NMRCO
Moscow, Russia